All endocrine glands are susceptible to neoplastic growth, yet the health consequences of
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …

Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Objective After temozolomide failure, no evidence-based treatment is available for pituitary
carcinomas (PCs) and aggressive pituitary tumors (APTs). To date, only 12 cases treated …

Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …

Pituitary adenomas (PAs) are benign lesions; nonetheless, some PAs exhibit aggressive
behaviors, which lead to recurrence. The impact of pituitary dysfunction, invasion-related …

Introduction Usually benign, pituitary tumors (PT) can be invasive and aggressive with a
propensity to progress and/or recur. Trouillas's clinicopathological classification attempts to …

Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors
(APTs) and carcinomas present important diagnostic and therapeutic challenges and are …

Objective Most pituitary tumours occur sporadically without a genetically identifiable
germline abnormality, a small but increasing proportion present with a genetic defect that …

Pituitary tumors (PT) are mostly benign, although occasionally they demonstrate aggressive
behavior, invasion of surrounding tissues, rapid growth, resistance to conventional …

After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …